Latham & Watkins Represents Underwriters in Phreesia’s Public Offering of Common Stock

Multidisciplinary team represented the underwriters in the offering by the patient intake management platform.

October 23, 2020

Phreesia, Inc., a leading patient intake management platform, has announced the pricing of its previously announced underwritten public offering of 5 million shares of its common stock at a price to the public of US$32 per share, all of which will be sold by the Company. In addition, the Company has granted the underwriters an option for 30 days to purchase up to 750,000 additional shares of common stock at the public offering price, less underwriting discounts. The Offering is expected to close on October 23, 2020, subject to the satisfaction of customary closing conditions. Phreesia expects to receive net proceeds from the offering of approximately US$151.6 million (or approximately US$174.4 million if the underwriters exercise their option to purchase additional shares in full) after deducting underwriting discounts and estimated offering expenses.

Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by New York partner Stelios Saffos, with associates Brittany Ruiz, Brian Yoon, and Egzon Sulejmani. Advice was also provided on tax matters by New York partner Jiyeon Lee-Lim, with associate Ron Moore; on payments matters by Washington, D.C. partner Todd Beauchamp, with associate Loyal Horsley; and on data privacy & cybersecurity matters by Washington, D.C. partner Jennifer Archie, with counsel Marissa Boynton.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.